{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T21:19:18Z","timestamp":1790543958042,"version":"4.1.0"},"reference-count":48,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Association for Training, Education, and Research in Hematology, Immunology, and Transplantation"},{"name":"Sanofi-Genzyme"}],"content-domain":{"domain":["bbmt.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biology of Blood and Marrow Transplantation"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1016\/j.bbmt.2018.01.005","type":"journal-article","created":{"date-parts":[[2018,1,11]],"date-time":"2018-01-11T14:28:58Z","timestamp":1515680938000},"page":"1013-1021","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":84,"title":["Sequential Conditioning with Thiotepa in T Cell- Replete Hematopoietic Stem Cell Transplantation for the Treatment of Refractory Hematologic Malignancies: Comparison with Matched Related, Haplo-Mismatched, and Unrelated Donors"],"prefix":"10.1016","volume":"24","author":[{"given":"R\u00e9my","family":"Dul\u00e9ry","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Lise","family":"M\u00e9nard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvain","family":"Chantepie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"El-Cheikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvie","family":"Fran\u00e7ois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00e9my","family":"Delage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Giannotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annalisa","family":"Ruggeri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eolia","family":"Brissot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgia","family":"Battipaglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florent","family":"Malard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramdane","family":"Belhocine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Sestili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Vekhoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Delhommeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oum\u00e9daly","family":"Reman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ollivier","family":"Legrand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myriam","family":"Labopin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Th\u00e9r\u00e8se","family":"Rubio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamad","family":"Mohty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbmt.2018.01.005_bib0010","first-page":"932","article-title":"Treatment of refractory AML","volume":"10","author":"Estey","year":"1996","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2018.01.005_bib0015","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1111\/j.1365-2141.2009.07917.x","article-title":"Failure of three novel regimens to improve outcome for patients with relapsed or refractory acute myeloid leukaemia: a report from the Eastern Cooperative Oncology Group","volume":"148","author":"Litzow","year":"2010","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2018.01.005_bib0020","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1182\/blood-2014-10-551911","article-title":"How I treat refractory and early relapsed acute myeloid leukemia","volume":"126","author":"Thol","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2018.01.005_bib0025","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1182\/blood-2006-05-018192","article-title":"Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12\/ECOG 2993 study","volume":"109","author":"Fielding","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2018.01.005_bib0030","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1182\/blood-2011-12-399287","article-title":"Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation","volume":"120","author":"G\u00f6kbuget","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2018.01.005_bib0035","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1182\/blood.V80.8.2142.2142","article-title":"Progressive disease after high-dose therapy and autologous transplantation for lymphoid malignancy: clinical course and patient follow-up","volume":"80","author":"Vose","year":"1992","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2018.01.005_bib0040","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1182\/blood-2009-09-245837","article-title":"A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)","volume":"115","author":"Passamonti","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2018.01.005_bib0045","doi-asserted-by":"crossref","first-page":"533","DOI":"10.3324\/haematol.10867","article-title":"Current status of reduced-intensity-conditioning allogeneic stem cell transplantation for acute myeloid leukemia","volume":"92","author":"Blaise","year":"2007","journal-title":"Haematologica"},{"key":"10.1016\/j.bbmt.2018.01.005_bib0050","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1182\/asheducation-2006.1.390","article-title":"Reduced-intensity regimens in allogeneic stem-cell transplantation for non-Hodgkin lymphoma and chronic lymphocytic leukemia","author":"Khouri","year":"2006","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.bbmt.2018.01.005_bib0055","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1038\/sj.leu.2403967","volume":"19","author":"Aoudjhane","year":"2005","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2018.01.005_bib0060","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1182\/blood-2005-10-4165","article-title":"Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantation","volume":"108","author":"Schmid","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2018.01.005_bib0065","doi-asserted-by":"crossref","first-page":"5675","DOI":"10.1200\/JCO.2005.07.061","article-title":"Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome","volume":"23","author":"Schmid","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2018.01.005_bib0070","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.bbmt.2008.03.005","article-title":"HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide","volume":"14","author":"Luznik","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2018.01.005_bib0075","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1016\/j.bbmt.2014.05.029","article-title":"Unmanipulated haploidentical transplants compared with other alternative donors and matched sibling grafts","volume":"20","author":"Raiola","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2018.01.005_bib0080","doi-asserted-by":"crossref","first-page":"3152","DOI":"10.1200\/JCO.2014.60.4777","article-title":"Outcomes of nonmyeloablative HLA-haploidentical blood or marrow transplantation with high-dose post-transplantation cyclophosphamide in older adults","volume":"33","author":"Kasamon","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2018.01.005_bib0085","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/bmt.2014.328","article-title":"Sequential therapy combining clofarabine and T-cell-replete HLA-haploidentical haematopoietic SCT is feasible and shows efficacy in the treatment of refractory or relapsed aggressive lymphoma","volume":"50","author":"Zoellner","year":"2015","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2018.01.005_bib0090","first-page":"736","article-title":"Phase I and pharmacokinetic evaluation of thiotepa in the cerebrospinal fluid and plasma of pediatric patients: evidence for dose-dependent plasma clearance of thiotepa","volume":"49","author":"Heideman","year":"1989","journal-title":"Cancer Res"},{"key":"10.1016\/j.bbmt.2018.01.005_bib0095","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1038\/sj.bmt.1705863","article-title":"Thiotepa-based reduced intensity conditioning regimen: a 10-year follow-up","volume":"40","author":"Bacigalupo","year":"2007","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2018.01.005_bib0100","first-page":"184","volume":"4","author":"Hiddemann","year":"1990","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2018.01.005_bib0105","doi-asserted-by":"crossref","first-page":"4642","DOI":"10.1200\/JCO.2003.04.036","article-title":"Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia","volume":"21","author":"Cheson","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2018.01.005_bib0110","doi-asserted-by":"crossref","first-page":"184","DOI":"10.3324\/haematol.2016.150326","article-title":"Sequential regimen of clofarabine, cytosine arabinoside and reduced-intensity conditioned transplantation for primary refractory acute myeloid leukemia","volume":"102","author":"Mohty","year":"2017","journal-title":"Haematologica"},{"issue":"11S","key":"10.1016\/j.bbmt.2018.01.005_bib0115","doi-asserted-by":"crossref","first-page":"S229","DOI":"10.1016\/j.bulcan.2016.09.007","article-title":"Haploidentical hematopoietic stem cell transplantation: guidelines from the Francophone Society of Marrow Transplantation and Cellular Therapy (SFGM-TC)]","volume":"103","author":"Nguyen","year":"2016","journal-title":"Bull Cancer"},{"key":"10.1016\/j.bbmt.2018.01.005_bib0120","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1038\/bmt.2015.305","article-title":"Definition of GvHD-free, relapse-free survival for registry-based studies: an ALWP-EBMT analysis on patients with AML in remission","volume":"51","author":"Ruggeri","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2018.01.005_bib0125","first-page":"825","article-title":"1994 Consensus Conference on Acute GVHD Grading","volume":"15","author":"Przepiorka","year":"1995","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2018.01.005_bib0130","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.bbmt.2014.12.001","article-title":"National Institutes of Health Consensus Development Project on criteria for clinical trials in chronic graft-versus-host disease, I: the 2014 Diagnosis and Staging Working Group report","volume":"21","author":"Jagasia","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2018.01.005_bib0135","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","article-title":"A proportional hazards model for the subdistribution of a competing risk","volume":"94","author":"Fine","year":"1999","journal-title":"J Am Stat Assoc"},{"key":"10.1016\/j.bbmt.2018.01.005_bib0140","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1200\/JCO.2012.44.3523","article-title":"T-cell-replete HLA-haploidentical hematopoietic transplantation for hematologic malignancies using post-transplantation cyclophosphamide results in outcomes equivalent to those of contemporaneous HLA-matched related and unrelated donor transplantation","volume":"31","author":"Bashey","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2018.01.005_bib0145","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.bbmt.2012.08.014","article-title":"Unmanipulated haploidentical bone marrow transplantation and posttransplantation cyclophosphamide for hematologic malignancies after myeloablative conditioning","volume":"19","author":"Raiola","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2018.01.005_bib0150","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1038\/bmt.2014.197","article-title":"Nonmyeloablative conditioning, unmanipulated haploidentical SCT and post-infusion CY for advanced lymphomas","volume":"49","author":"Castagna","year":"2014","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2018.01.005_bib0155","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1038\/bmt.2013.166","article-title":"Unmanipulated haploidentical BMT following non-myeloablative conditioning and post-transplantation CY for advanced Hodgkin's lymphoma","volume":"49","author":"Raiola","year":"2014","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2018.01.005_bib0160","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1038\/leu.2015.98","article-title":"Comparison of outcomes after unrelated cord blood and unmanipulated haploidentical stem cell transplantation in adults with acute leukemia","volume":"29","author":"Ruggeri","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2018.01.005_bib0165","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1016\/j.bbmt.2012.07.003","article-title":"Improved early outcomes using a T cell-replete graft compared with T cell depleted haploidentical hematopoietic stem cell transplantation","volume":"18","author":"Ciurea","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2018.01.005_bib0170","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.bbmt.2015.09.002","volume":"22","author":"Bashey","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2018.01.005_bib0175","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/sj.bmt.1705207","article-title":"Allogeneic stem-cell transplantation in patients with refractory acute leukemia: a long-term follow-up","volume":"37","author":"Oyekunle","year":"2006","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2018.01.005_bib0180","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/sj.bmt.1703373","article-title":"Allogeneic transplantation from HLA-matched sibling or partially HLA-mismatched related donors for primary refractory acute leukemia","volume":"29","author":"Singhal","year":"2002","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2018.01.005_bib0185","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1038\/sj.bmt.1705965","article-title":"High antileukemic efficacy of an intermediate intensity conditioning regimen for allogeneic stem cell transplantation in patients with high-risk acute myeloid leukemia in first complete remission","volume":"41","author":"Schmid","year":"2008","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2018.01.005_bib0190","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/bmt.2011.15","article-title":"Early allo-SCT for AML with a complex aberrant karyotype: results from a prospective pilot study","volume":"47","author":"Schmid","year":"2012","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2018.01.005_bib0195","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1111\/ejh.12522","article-title":"Allogeneic stem cell transplantation for refractory acute myeloid leukemia: a single center analysis of long-term outcome","volume":"95","author":"Hemmati","year":"2015","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.bbmt.2018.01.005_bib0200","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1182\/blood-2002-05-1340","volume":"101","author":"Niederwieser","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2018.01.005_bib0205","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1182\/blood.V80.4.1090.1090","article-title":"Bone marrow transplants may cure patients with acute leukemia never achieving remission with chemotherapy","volume":"80","author":"Biggs","year":"1992","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2018.01.005_bib0210","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1038\/leu.2010.200","article-title":"Antithymocyte globulins and chronic graft-vs-host disease after myeloablative allogeneic stem cell transplantation from HLA-matched unrelated donors: a report from the Soci\u00e9te Fran\u00e7aise de Greffe de Moelle et de Th\u00e9rapie Cellulaire","volume":"24","author":"Mohty","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2018.01.005_bib0215","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.bbmt.2005.12.034","article-title":"Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation","volume":"12","author":"Bacigalupo","year":"2006","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2018.01.005_bib0220","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.bbmt.2014.01.016","article-title":"Antithymocyte globulin before allogeneic stem cell transplantation for progressive myelodysplastic syndrome: a study from the French Society of Bone Marrow Transplantation and Cellular Therapy","volume":"20","author":"Dul\u00e9ry","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2018.01.005_bib0225","doi-asserted-by":"crossref","first-page":"3024","DOI":"10.1182\/blood-2015-01-623991","article-title":"Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide","volume":"125","author":"McCurdy","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2018.01.005_bib0230","doi-asserted-by":"crossref","first-page":"3361","DOI":"10.1182\/blood-2011-09-377044","article-title":"Azacitidine augments expansion of regulatory T cells after allogeneic stem cell transplantation in patients with acute myeloid leukemia (AML)","volume":"119","author":"Goodyear","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2018.01.005_bib0235","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/j.bbmt.2016.01.013","article-title":"Allogeneic hematopoietic stem cell transplantation in FLT3-ITD-positive acute myelogenous leukemia: the role for FLT3 tyrosine kinase inhibitors post-transplantation","volume":"22","author":"Schiller","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2018.01.005_bib0240","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1038\/bmt.2016.251","article-title":"Inhibition of FLT3 in AML: a focus on sorafenib","volume":"52","author":"Antar","year":"2017","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2018.01.005_bib0245","doi-asserted-by":"crossref","first-page":"2867","DOI":"10.1002\/cncr.30680","article-title":"Efficacy and feasibility of sorafenib as a maintenance agent after allogeneic hematopoietic stem cell transplantation for Fms-like tyrosine kinase 3-mutated acute myeloid leukemia","volume":"123","author":"Battipaglia","year":"2017","journal-title":"Cancer"}],"container-title":["Biology of Blood and Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S108387911830020X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S108387911830020X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T15:02:56Z","timestamp":1761058976000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S108387911830020X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":48,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["S108387911830020X"],"URL":"https:\/\/doi.org\/10.1016\/j.bbmt.2018.01.005","relation":{},"ISSN":["1083-8791"],"issn-type":[{"value":"1083-8791","type":"print"}],"subject":[],"published":{"date-parts":[[2018,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sequential Conditioning with Thiotepa in T Cell- Replete Hematopoietic Stem Cell Transplantation for the Treatment of Refractory Hematologic Malignancies: Comparison with Matched Related, Haplo-Mismatched, and Unrelated Donors","name":"articletitle","label":"Article Title"},{"value":"Biology of Blood and Marrow Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbmt.2018.01.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 American Society for Blood and Marrow Transplantation.","name":"copyright","label":"Copyright"}]}}